Kadmon (KDMN) & Cesca Therapeutics (NASDAQ:KOOL) Financial Review

Cesca Therapeutics (NASDAQ: KOOL) and Kadmon (NYSE:KDMN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Cesca Therapeutics has a beta of -0.77, indicating that its share price is 177% less volatile than the S&P 500. Comparatively, Kadmon has a beta of 3.97, indicating that its share price is 297% more volatile than the S&P 500.

Institutional & Insider Ownership

2.6% of Cesca Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Kadmon shares are owned by institutional investors. 3.9% of Cesca Therapeutics shares are owned by insiders. Comparatively, 8.4% of Kadmon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cesca Therapeutics and Kadmon, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cesca Therapeutics 0 1 0 0 2.00
Kadmon 1 0 3 0 2.50

Kadmon has a consensus target price of $13.25, suggesting a potential upside of 238.01%. Given Kadmon’s stronger consensus rating and higher possible upside, analysts plainly believe Kadmon is more favorable than Cesca Therapeutics.


This table compares Cesca Therapeutics and Kadmon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cesca Therapeutics -43.35% -17.76% -11.64%
Kadmon -650.47% N/A -110.26%

Valuation and Earnings

This table compares Cesca Therapeutics and Kadmon’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cesca Therapeutics $14.52 million 1.31 -$29.09 million N/A N/A
Kadmon $12.26 million 25.14 -$79.77 million ($1.42) -2.76

Cesca Therapeutics has higher revenue and earnings than Kadmon.


Kadmon beats Cesca Therapeutics on 8 of the 12 factors compared between the two stocks.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Kadmon Company Profile

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply